







Recombinant Protein Products


Brand name	Generic name	Product Description	Indication	Presentations	Storage condition	Shelf-life
GreenGene F inj. 	Beractocog alfa (Antihemophilic factor VIII)	A lyophilized concentrate of B-domain deleted recombinant factor VIII from CHO cells in a perfusion culture system using an animal source-free medium. Plasma & Albumin are not used in the cell culture and purification processes, and the final formulation. It is treated with S/D treatment and nano-filtration for viral inactivation.	For prevention and control of bleeding episodes and perioperative management in hemophilia A	250 IU 500 IU 1,000 IU	2~8 °C	24 months
Hunterase inj. 	Idursulfase-β	The recombinant human iduronate-2-sulfatase for mucopolysaccharidosis type II (Hunter syndrome) for intravenous infusion, using serum-free manufacturing process.	For the treatment of patients with mucopolysaccharidosis type II (Hunter syndrome) as an enzyme replacement therapy (ERT)	6 mg 3 mL / 1 vial	2~8 °C	36 months
Hunterase ICV inj. 	Idursulfase-β	The recombinant human iduronate-2-sulfatase for mucopolysaccharidosis type II (Hunter syndrome) for intracerebroventricular injection, using serum-free manufacturing process.	For the treatment of neuropathic mucopolysaccharidosis type II patients (Hunter syndrome) as an enzyme replacement therapy (ERT)	15 mg 1 mL / 1 vial	2~8 °C	24 months
Neulapeg PFS inj. 	Pegteograstim	The PEGylated recombinant human granulocyte colony stimulating factor (G-CSF) for subcutaneous injection, produced from E-coli and a preservative-free formulation.	For decreasing the duration of severe neutropenia in cancer patients treated with myelosuppressive chemotherapy	6 mg / 0.6 mL Pre-filled syringe	2~8 °C	36 months

OTC Products (Patches)







Brand name	Generic name	Product Description	Indication	Presentations	Storage condition	Shelf-life
Acustop cataplasma 	Flurbiprofen	Provides anti-inflammatory and analgesic effects for musculoskeletal and joint disorders by transdermal absorption.	Arthritis deformans, peri-arthritis humero-scapularis, tendinitis, peritendinitis, humeral epicondylitis, sore muscle, swelling, pain resulting from trauma.	6 sheets (1 sheet : 10 X 14 cm ²)	1~30 °C	36 months
Kenhancer plaster 	Ketoprofen	Provides anti-inflammatory, analgesic effects targeting the painful area via TDDS (Transdermal Drug Delivery System).	Arthritis deformans, peri-arthritis humero-scapularis, tendinitis, peritendinitis, humeral epicondylitis, sore muscle, swelling, pain resulting from trauma.	6 sheets (1 sheet : 7 X 10 cm ²)	1~30 °C	36 months



CORE PRODUCTS

GC Biopharma is a Global Biotech Leader in saving and improving lives and offers a broad range of vaccines, plasma derivatives and therapies for rare diseases.






Plasma Derivatives

Brand name	Generic name	Product Description	Indication	Presentations	Storage condition	Shelf-life
ALBUMIN-GCC inj. 	Normal Human Serum Albumin, 20%	A 20% sterile solution of human albumin prepared with cold ethanol fractionation method from pooled plasma obtained from healthy donor, and tested negative for HBsAg, anti- HIV, anti-HCV, etc. It is treated with heat at 60 °C for 10 hours for viral inactivation.	For hypoalbuminemia and shock in acute hemorrhage by loss of albumin (burns, nephrotic syndromes, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)	20% 50 mL 20% 100 mL	≤30 °C without freezing	39 months
I.V.-Globulin SN inj. 	Human Normal Immunoglobulin for Intravenous Administration, 5%	A sterile solution of human immunoglobulin preparation for intravenous use produced by cold ethanol fractionation, from pooled plasma of healthy donors, and tested negative for HBsAg, anti-HIV, anti-HCV, etc. It is treated with chromatographic purification, S/D treatment and nano-filtration are included in the production process for viral clearance.	1. A-/hypo-gammaglobulinemia 2. Combined therapy with antibiotics for severe bacterial or viral infections 3. Idiopathic thrombocytopenic purpura 4. Guillain-barre syndrome 5. Kawasaki syndrome	50 mL 100 mL 200 mL	2~8 °C	30 months
Eugamma SN 10% inj. 	Human Normal Immunoglobulin for Intravenous Administration, 10%	A sterile solution of human immunoglobulin preparation for intravenous use produced by cold ethanol fractionation, from pooled plasma of healthy donors, and tested negative for HBsAg, anti-HIV, anti-HCV, etc. It is treated with chromatographic purification, S/D treatment and nano-filtration are included in the production process for viral clearance.	1. A-/hypo-gammaglobulinemia 2. Combined therapy with antibiotics for severe bacterial or viral infections 3. Idiopathic thrombocytopenic purpura 4. Guillain-barre syndrome 5. Kawasaki syndrome	10 mL 25 mL 50 mL 100 mL 200 mL	1~25 °C	36 months
Hepabig inj. 	Human Hepatitis B Immunoglobulin	A sterile solution of hepatitis B immunoglobulin prepared by cold ethanol fractionation from pooled plasma of individuals with high titers of anti-HBs, and tested negative for HBsAg, anti-HIV, anti-HCV, etc. It is treated with heat at 60 °C for 10 hours for viral inactivation.	1. For prophylaxis of hepatitis B after exposure to HBsAg 2. For prophylaxis of hepatitis B in neonates	100 IU / 0.5 mL 200 IU / 1.0 mL	2~8 °C	30 months
I.V.-Hepabig inj. 	Human Hepatitis B Immunoglobulin for Intravenous Administration	A sterile solution (colorless or light brown) product for intravenous use produced by cold ethanol fractionation from pooled hepatitis B plasma, and tested negative for HBsAg, anti-HIV, anti-HCV, etc. It is treated with chromatographic purification, S/D treatment and ultrafiltration are included in the production process for viral clearance.	For prevention of recurrence of hepatitis B in patients with liver transplant	2,000 IU / 10 mL	2~8 °C	30 months
Sero-Tet inj. 	Human Tetanus Immunoglobulin	A sterile solution of tetanus immunoglobulin prepared by cold ethanol fractionation from pooled tetanus hyperimmune plasma, and tested negative for HBsAg, anti-HIV, anti-HCV, etc. It is treated with heat at 60 °C for 10 hours for viral inactivation.	For prophylaxis of tetanus and reduction of tetanus symptoms by providing passive immunization against infection caused by Clostridium tetani	250 IU	2~8 °C without freezing	38 months

Varicella Zoster Immune Globulin-GCC inj. 	Human Varicella Immunoglobulin	A sterile solution of Varicella Zoster immunoglobulin(VZIG) prepared by cold ethanol fractionation from pooled plasma of individuals with high titers of VZIG, and tested negative for HBsAg, anti-HIV, anti-HCV, etc. It is treated with heat at 60 °C for 10 hours for viral inactivation.	For passive immunity to Varicella Zoster virus for post-exposure prophylaxis of immunodeficiency children	125 IU / 2.5 mL 250 IU / 5 mL	2~8 °C	24 months
GREEN-VIII inj. 	Human Coagulation Factor VIII	A lyophilized concentrate of human anti-hemophilic factor (AHF, factor VIII) prepared from pooled plasma of healthy donors, and tested negative for HBsAg, anti-HIV, anti-HCV, etc. It is treated with solvent-detergent (TNBP & Tween 80) and heat for viral inactivation.	For treatment of hemophilia A	250 IU 500 IU	2~8 °C	30 months

Vaccines

Brand name	Generic name	Product Description	Indication	Presentations	Storage condition	Shelf-life
BARYCELA inj. 	Varicella Vaccine	Lyophilized, live attenuated varicella vaccine.	For prophylaxis against varicella	≥ 3,800 PFU / 0.5mL (0.7 mL when reconstituted with diluent)	2~8 °C	24 months
GC FLU inj. 	Seasonal Influenza Vaccine	Trivalent, made by splitting and inactivating influenza virus cultured by inoculating the allantoic cavity of embryonated eggs in order to maintain antigenicity.	For prophylaxis against influenza	0.5 mL (PFS) 0.25 mL (PFS) 0.5 mL (vial) 5 mL (vial)	2~8 °C	12 months
GC FLU Quadrivalent inj. 	Seasonal Influenza Vaccine	Quadrivalent, made by splitting and inactivating influenza virus cultured by inoculating the allantoic cavity of embryonated eggs in order to maintain antigenicity.	For prophylaxis against influenza	0.5 mL (PFS) 0.5 mL (vial) 5 mL (vial)	2~8 °C	12 months